ArticleThe Journal of biological chemistry2012
Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation.
Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed.
- DNA Methylation as a Programmable Information Layer: From Molecular Marks to Disease State Engineering.International journal of molecular sciences · 2026Review
- Epigenetic editing approaches maturity: AI-driven precision design, delivery innovation, and the road to clinical translation.Clinical epigenetics · 2026Review
- Using ngTALEN to improve genome editing efficiency on targets containing 5-methylcytosines.The Plant journal : for cell and molecular biology · 2026Article
- Mitochondrial diseases: from molecular mechanisms to therapeutic advances.Signal transduction and targeted therapy · 2025Review
- Comprehensive analysis of the editing window of C-to-T TALE base editors.Scientific reports · 2024Article
- Improving cassava bacterial blight resistance by editing the epigenome.Nature communications · 2023Article
- Gene Editing Technologies to Target HBV cccDNA.Viruses · 2022Review
- Review
- CRISPR-Cas-mediated transcriptional control and epi-mutagenesis.Plant physiology · 2022Review
- Efficient multitool/multiplex gene engineering with TALE-BE.Frontiers in bioengineering and biotechnology · 2022Article
- Epigenetic features improve TALE target prediction.BMC genomics · 2021Article
- TALENs-an indispensable tool in the era of CRISPR: a mini review.Journal, genetic engineering & biotechnology · 2021Review
- Applications and Major Achievements of Genome Editing in Vegetable Crops: A Review.Frontiers in plant science · 2021Review
- Targeted gene therapy into a safe harbor site in human hematopoietic progenitor cells.Gene therapy · 2020Article
- CRISPR/Cas: a potential gene-editing tool in the nervous system.Cell regeneration (London, England) · 2020Review
- Review
- Challenges and Perspectives in Homology-Directed Gene Targeting in Monocot Plants.Rice (New York, N.Y.) · 2019Review
- Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9.eLife · 2019Article
- The diverse roles of DNA methylation in mammalian development and disease.Nature reviews. Molecular cell biology · 2019Review
- The Chromatin Structure of CRISPR-Cas9 Target DNA Controls the Balance between Mutagenic and Homology-Directed Gene-Editing Events.Molecular therapy. Nucleic acids · 2019Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the past 2 years, transcription activator-like effector (TALE) DNA binding domains have emerged as the new generation of engineerable platform for production of custom DNA binding domains. However, their recently described sensitivity to cytosine methylation represents a major bottleneck for genome engineering applications. Using a combination of biochemical, structural, and cellular approaches, we were able to identify the molecular basis of such sensitivity and propose a simple, drug-free, and universal method to overcome it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.